🇺🇸 FDA
Pipeline program

Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

SP_MH19PRO

Phase 3 small_molecule active

Quick answer

Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution for Acute myeloid leukemia is a Phase 3 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
AXIM BIOTECHNOLOGIES, INC.
Indication
Acute myeloid leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials